未登录 分享 收藏
分享 收藏
分享 收藏
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors 首次人体I期开放标签研究：LAG-3拮抗剂抗体INCAGN02385在特定晚期或转移性实体瘤患者中的应用 Powderly II, John D.; Gutierrez, Martin E.; Balmanoukian, Ani S.; Hoyle, Paul E.; Dong, Zhiwan; Cheng, Lulu; Chen, Xuejun; Janik, John E.; Bourayou, Nawel; Hamid, Omid 分享 收藏
Shared decision making in routine oncology appointments with Black patients with lung cancer 与黑人肺癌患者进行常规肿瘤学就诊时的共同决策制定 Aubuchon, Katarina E.; Khoudary, Amanda; Rodriguez, Jennifer D.; Billini, Osairys M.; Westervelt, Isabella; Taylor, Emily P.; Newton, Noelle; Emenyonu, Melody; Kim, Chul; Veystman, Irina; Wheeley, Jennifer; Gutierrez, Martin; Derry-Vick, Heather M.; Conley, Claire C. 分享 收藏
Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors Doi, T.; Patel, M. R.; Koyama, T.; Falchook, G. S.; Friedman, C.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M.; Mattour, A.; Satoh, T.; Takahashi, S.; Tsunoda, T.; Kadowaki, S.; Watanabe, Y.; Okamoto, N.; Goto, H.; Yoshizuka, N.; Qian, M.; Qian, X.; Johnson, M. 分享 收藏
Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study 系统性STING激动剂BI 1703880联合ezabenlimab在晚期实体瘤患者(pts)中的研究：Ia期研究的初步结果 Harrington, K. J.; Kitano, S.; Gambardella, V.; Parkes, E. E.; Moreno Candilejo, I.; Alonso Casal, G.; Doi, T.; Berz, D.; Gutierrez, M.; Fernandez, N.; Li, B.; Barrueco, J.; Lorusso, P. 分享 收藏
Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors ATR抑制剂IMP9064单药治疗在晚期实体瘤患者中的首次人体研究的剂量递增结果 Lin, C-C.; Schneider, R.; Gutierrez, M.; Shen, L.; Chung, K.; Doroshow, D. B.; Gao, B.; Millward, M.; Hsieh, C-Y.; Xu, C.; Cai, S. X.; Tian, Y. E.; Liu, L.; Shen, C.; Tan, Y.; He, Y.; Zhang, C.; Li, L.; Ma, M.; Xu, L. 分享 收藏
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study 在1期KEYNOTE-603研究中，单独或与Pembrolizumab联合使用个体化新抗原治疗mRNA-4157 (V940) 的T细胞反应 Gainor, Justin F.; Patel, Manish R.; Weber, Jeffrey S.; Gutierrez, Martin; Bauman, Julie E.; Clarke, Jeffrey M.; Julian, Ricklie; Scott, Aaron J.; Geiger, Jessica L.; Kirtane, Kedar; Robert-Tissot, Celine; Coder, Brandon; Tasneem, Moomal; Sun, Jing; Zheng, Wei; Gerbereux, Lauren; Laino, Andressa; Porichis, Filippos; Pollard, Jack Russella; Hou, Peijie; Sehgal, Vasudha; Chen, Xing; Morrissey, Manju; Daghestani, Hikmat N.; Feldman, Igor; Srinivasan, Lakshmi; Frederick, Joshua P.; Brown, Michelle; Aanur, Praveen; Meehan, Robert; Burris III, Howard A. 分享 收藏
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies Saleh, M.; Barve, M.; Subbiah, V.; Papadopoulos, K. P.; Morgensztern, D.; Mettu, N. B.; Roychowdhury, S.; Spanggaard, I.; Veronese, M. L.; Tian, C.; Silverman, I. M.; Gutierrez, M. 分享 收藏
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers Keller, Patricia J.; Adams, Elizabeth J.; Wu, Rentian; Cote, Alexandre; Arora, Shilpi; Cantone, Nico; Meyer, Rosana; Mertz, Jennifer A.; Gehling, Victor; Cui, Jike; Stuckey, Jacob I.; Khanna, Avinash; Zhao, Feng; Chen, Zehua; Yu, Ziyang; Cummings, Richard T.; Taimi, Mohammed; Lakhani, Nehal J.; Rasco, Drew; Gutierrez, Martin; Duska, Linda; Devitt, Michael; Rippley, Ronda; Levell, Julian; Truong, Jennifer; Wang, Jing; Sun, Kaiming; Trojer, Patrick 分享 收藏
Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor Garralda, Elena; Boni, Valentina; Baz, David Vincente; Chaudhry, Arvind; Bazo, Ignacio Gil; Gutierrez, Martin; Malhotra, Jyoti; Alonso, Casal Guzman; Gambardella, Valentina; Chisamore, Michael; Zhou, Renke; Tea, Maria; Doroshow, Deborah 分享 收藏
分享 收藏
Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors Siu, Lillian L.; Gil-Martin, Marta; Cho, Byoung Chul; Perets, Ruth; Hilton, John; Geva, Ravit; Lugowska, Iwona; Gutierrez, Martin; Bonomi, Marcelo; Dziadziuszko, Rafal; Rasco, Drew; Ben-Ami, Eytan; Rodriguez, Cristina P.; Siddiqi, Shabana; Myer, Nicole; Suttner, Leah; Wilson, Douglas; Akala, Ombololaji O.; de Miguel, Maria 分享 收藏
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors MEK抑制剂selumetinib联合pembrolizumab治疗晚期或转移性实体瘤的1期试验 Chenard-Poirier, Maxime; Hansen, Aaron R.; Gutierrez, Martin E.; Rasco, Drew; Xing, Yan; Chen, Lin-Chi; Zhou, Heng; Webber, Andrea L.; Freshwater, Tomoko; Sharma, Manish R. 分享 收藏
An intronic RNA element modulates Factor VIII exon-16 splicing Tse, Victor; Chacaltana, Guillermo; Gutierrez, Martin; Forino, Nicholas M.; Jimenez, Arcelia G.; Tao, Hanzhang; Do, Phong H.; Oh, Catherine; Chary, Priyanka; Quesada, Isabel; Hamrick, Antonia; Lee, Sophie; Stone, Michael D.; Sanford, Jeremy R. 分享 收藏
Predicting PD-L1 Status in Solid Tumors Using Transcriptomic Data and Artificial Intelligence Algorithms Charifa, Ahmad; Lam, Alfonso; Zhang, Hong; Ip, Andrew; Pecora, Andrew; Waintraub, Stanley; Graham, Deena; Mcnamara, Donna; Gutierrez, Martin; Jennis, Andrew; Sharma, Ipsa; Estella, Jeffrey; Ma, Wanlong; Goy, Andre; Albitar, Maher 分享 收藏
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study 晚期实体瘤患者的Ifinatamab deruxtecan (i-dxd; DS-7300): I/II期研究的最新临床和生物标志物结果 Patel, M. R.; Doi, T.; Koyama, T.; Falchook, G. S.; Friedman, C. F.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M. M.; Mattour, A. H.; Satoh, T.; Okamoto, N.; Singh, J.; Yoshizuka, N.; Qian, M.; Qian, X.; Tran, B. P.; Dosunmu, O.; Lu, P.; Johnson, M. L. 分享 收藏
Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial Pant, S.; Arnold, D.; Tabernero, J.; Loriot, Y.; Folprecht, G.; Haag, G. M.; Palmer, D.; Prenen, H.; Coward, J.; Lugowska, I.; Goeminne, J-C.; Cervantes, A.; Gutierrez, M.; Sweiti, H.; Hammond, C.; Najmi, S.; Thomas, S.; Triantos, S.; Crow, L.; Schuler, M. H. H. 分享 收藏
First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors Lin, C-C.; Schneider, R. E.; Gutierrez, M.; Shen, L.; Gao, B.; Chung, K.; Doroshow, D. B.; Millward, M.; Hsieh, C-Y.; Xu, C.; Cai, S. X.; Tian, Y. E.; Liu, L.; Shen, C.; Li, B.; Tan, Y.; Zhang, C.; Li, L.; Ma, M.; Chen, X. 分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
